Submission Details
| 510(k) Number | K242683 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | September 06, 2024 |
| Decision Date | March 18, 2025 |
| Days to Decision | 193 days |
| Submission Type | Traditional |
| Review Panel | Radiology (RA) |
| Summary | Summary PDF |
K242683 is an FDA 510(k) clearance for the QP-Prostate? CAD, a Radiological Computer Assisted Detection/diagnosis Software For Lesions Suspicious For Cancer (Class II — Special Controls, product code QDQ), submitted by Quibim S.L. (Valencia, ES). The FDA issued a Cleared decision on March 18, 2025, 193 days after receiving the submission on September 6, 2024. This device falls under the Radiology review panel. Regulated under 21 CFR 892.2090.
| 510(k) Number | K242683 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | September 06, 2024 |
| Decision Date | March 18, 2025 |
| Days to Decision | 193 days |
| Submission Type | Traditional |
| Review Panel | Radiology (RA) |
| Summary | Summary PDF |
| Product Code | QDQ — Radiological Computer Assisted Detection/diagnosis Software For Lesions Suspicious For Cancer |
| Device Class | Class II — Special Controls |
| CFR Regulation | 21 CFR 892.2090 |
| Definition | A Radiological Computer Assisted Detection And Diagnostic Software For Suspected Lesions Is An Image Processing Device Intended To Aid In The Detection, Localization, And Characterization Of Lesions Suspicious For Cancer On Acquired Medical Images (e.g., Mammography , Mr, Ct, Ultrasound, Radiography). The Device Detects, Identifies And Characterizes Lesions Suspicious For Cancer Based On Features Or Information Extracted From The Images, And May Provide Information About The Presence, Location, And Characteristics Of The Lesion To The User. Primary Diagnostic And Patient Management Decisions Are Made By The Clinical User. |